The global gene
therapy market size is expected to reach USD 39.54 million by
2026. Rising competition among manufacturers and high number of molecules in
pipeline are supporting the growth of the market.
Gene therapy development is aimed to cure rare
diseases and even some hereditary diseases, which are caused by a mutated or
faulty gene. Moreover, ever-increasing need for new cures for orphan diseases
and rising incidence of cancer caused due to mutations in genes are likely to
stir up the demand for gene therapy.
As of early 2016, there were more than 1000 molecules
in the pipeline in various clinical phases. However, around 76.0% of the
molecules are in the developmental or preclinical stages and expected to hit
the market in late 2020’s.
A great number of large pharma/biotech players are
estimated to acquire small firms as many have been trying to develop in-house
expertise and build their own pipelines. This trend is anticipated to help the
market gain tremendous traction over the coming years. Combination of gene
therapy with small molecules or protein therapy is said to have lesser side
effects and better efficacy as compared to gene therapy alone.
Cancer held the dominant share in the market in 2017
owing to relatively high adoption of gene therapies for cancer treatment.
Continual rise in new cancer cases and related mortality per year triggers the
need for development of robust treatment options. Ongoing developments in
cancer gene studies have provided significant information about cancer-related
molecular signatures, which in turn, is projected to support ongoing clinical
trials for cancer therapeutics
Browse full research report on Gene Therapy Market: https://www.grandviewresearch.com/industry-analysis/gene-therapy-market
Further Key Findings from the Study Suggest:
- More than 60.0% of the market is occupied by cancer research owing
to a large pipeline.
- Adenoviral vectors are the most used in pipeline development,
closely followed by retroviral vectors.
- Europe and the U.S. are poised to occupy the largest cumulative
share in the market throughout the forecast period.
- Asia Pacific is set to post noteworthy CAGR during the forecast
period, owing to growing pipeline molecules and a large number of
companies competing in the market.
- Some of the key players in this market are UniQure N.V, Spark
Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline,
Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension
Therapeutics, Voyager Therapeutics, Human Stem Cell Institute, Bristol
Myer’s Squibb, and Chiesi Farmaceutici S.p.A.
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/biotechnology
Grand
View Research has segmented the global gene therapy market by indication,
vector type, and region:
Gene
Therapy Indication Outlook (Revenue, USD Million, 2014 - 2026)
- Cancer
- Cardio
Vascular Diseases
- Infectious
Diseases
- Genetic
Disorders
- Neuro
Disorders
- Others
Gene
Therapy Vector Type Outlook (Revenue, USD Million, 2014 - 2026)
- Viral Vectors
- Retrovirus
- Adenovirus
- Adeno-associated
virus
- Vaccinia
virus
- Herpes
simplex virus
- Others
- Non-Viral
Vectors
- Injection of
Naked DNA
- Lipofection
- Others
Gene
Therapy Regional Outlook (Revenue, USD Million, 2014 - 2026)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- MEA
- South Africa
About Grand View
Research
Grand View Research, Inc. is a U.S. based market research
and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports,
customized research reports, and consulting services. To help clients make
informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
No comments:
Post a Comment